PSC investors benefit from Section 1202 of the Internal Revenue Code which offers a significant tax incentive.
Aging is a universal part of life, but have you ever wondered why some people seem to age more gracefully than others? The answer lies hidden within our genes, and a fascinating field of science known as epigenetics is shedding light on this timeless mystery.
Growth factors have the potential to be a useful tool in regenerative medicine but more studies are needed to ensure their safe and effective use.
While exosome therapy is a burgeoning field, there are currently no FDA approved exosome treatments as more studies are needed to confirm the safety and efficacy of such products.
Expanded access is an FDA program that under certain conditions allows the use of an investigational new drug (IND) to treat a patient with a serious or life-threatening disease outside of a clinical trial.
The Right to Try Act provides a new channel for eligible patients to request access to investigational drugs outside of their ongoing clinical trial.
The Right to Try Act allows patients access to treatments that are in the FDA’s drug approval pipeline but not yet approved.
As the science of aging expands its knowledge of all the changes and challenges of aging, the use of stem cells for anti-aging will become one of the standards of care.
Over thirty years ago Dr. Arnold Caplan coined the term MSCs and since then there have been thousands of clinical trials involving the use of adult stem cells.
There are a number of cellular interventions that are currently being studied for the treatment of various diseases.